Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668662 | 0.89 | CXCR3 (0.48) | CXCR3HTTOGAACKR3MCHR1 | |
| SCHEMBL4615331 | 0.89 | CXCR3 (0.49) | CXCR3HTTOGAACKR3MCHR1 | |
| SCHEMBL14396723 | 0.88 | ABL1 (0.42) | CXCR3ACKR3KMT2A | |
| SCHEMBL4616552 | 0.88 | CXCR3 (0.42) | CXCR3MCHR1KMT2AMEN1 | |
| SCHEMBL4615215 | 0.80 | HSP90AA1 (0.49) | ALDH1A1CYP2D6ACKR3CTNNB1TCF7L2 | |
| SCHEMBL4808903 | 0.77 | CXCR3 (0.41) | CXCR3HTTOGAMCHR1KMT2A | |
| SCHEMBL4616629 | 0.77 | CXCR3 (0.42) | CXCR3HTTOGAMCHR1KMT2A | |
| SCHEMBL14396550 | 0.75 | DRD2 (0.52) | ACKR3 | |
| SCHEMBL14396551 | 0.74 | DRD2 (0.47) | HTTACKR3KMT2A | |
| SCHEMBL4615593 | 0.74 | DRD2 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | H. LUNDBECK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7329656-B2 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-02-12 | — | — | US | disclosed |
| EP-1799223-A4 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | LUNDBECK & CO AS H (DK) | 2008-01-23 | — | — | EP | disclosed |
| EP-1799223-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | H.Lundbeck A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006041635-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2006-04-13 | — | — | US | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | CXCR3 2129/4885HTT 256/4885OGA 3538/4885 |
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | MCHR1, MC4R, MCHR2 | CXCR3 541/4885HTT 93/4885OGA 4098/4885 |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | MCHR1, MC4R, MCHR2 | CXCR3 590/4885HTT 101/4885OGA 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.